Education
About Us
Working with TipRanks
Follow Us
Eisai Co Ltd (DE:EII)
FRANKFURT:EII
EII Stock Chart & Stats
€26.63
€0.72(2.72%)
At close: 4:00 PM EST
€26.63
€0.72(2.72%)
Day’s Range― - ―
52-Week Range€21.45 - €31.41
Previous CloseN/A
Volume159.00
Average Volume (3M)145.00
Market Cap
€7.52B
Enterprise Value€1.28T
Total Cash (Recent Filing)€285.38B
Total Debt (Recent Filing)€238.92B
Price to Earnings (P/E)19.1
Beta0.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding291,649,140
10 Day Avg. Volume205
30 Day Avg. Volume145
Financial Highlights & Ratios
PEG Ratio2.35
Price to Book (P/B)1.40
Price to Sales (P/S)1.49
P/FCF Ratio64.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.64Price Target Upside11.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundA 47.2% TTM revenue rebound indicates durable product traction and demand across Eisai's core therapeutic areas. Sustained top-line growth improves funding capacity for R&D and lifecycle expansion, bolstering long-term commercial momentum and strategic optionality.
High Gross MarginA ~78% gross margin reflects pricing power and a favorable branded-product mix, supporting durable profitability even with heavy R&D spending. High gross margins provide operating leeway for clinical investment and help preserve cash flow through reimbursement cycles.
Conservative LeverageLow leverage (D/E ~0.28) and a large equity base give Eisai financial flexibility to fund ongoing development, pursue selective M&A, and absorb reimbursement timing shocks. A conservative balance sheet supports multi-quarter resilience in capital allocation.
Bears Say
Cash-flow VolatilityHistoric swings in operating and free cash flow reduce predictability of internal funding for trials and commercialization. FCF/NetIncome ~0.75 shows conversion below parity, increasing reliance on timing decisions for working capital or external funding in weaker periods.
Moderate ROEAn ROE around 5.8% suggests only modest capital efficiency versus typical specialty pharma expectations. Persistently mid-single-digit returns can constrain shareholder value creation and imply that heavy reinvestment or pricing pressures limit profit conversion from growing revenues.
Limited Net Margin LeverageDespite strong gross margins, net margin near 6.1% and an EBIT margin ~8.6% indicate constrained bottom-line leverage, likely from R&D and SG&A intensity and pricing/reimbursement pressures. This limits free cash flow expansion relative to revenue gains.
Eisai Co News
EII FAQ
What was Eisai Co Ltd’s price range in the past 12 months?
Eisai Co Ltd lowest stock price was €21.45 and its highest was €31.41 in the past 12 months.
What is Eisai Co Ltd’s market cap?
Eisai Co Ltd’s market cap is €7.52B.
When is Eisai Co Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eisai Co Ltd’s earnings last quarter?
Currently, no data Available
Is Eisai Co Ltd overvalued?
According to Wall Street analysts Eisai Co Ltd’s price is currently Undervalued.
Does Eisai Co Ltd pay dividends?
Eisai Co Ltd does not currently pay dividends.
What is Eisai Co Ltd’s EPS estimate?
Eisai Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eisai Co Ltd have?
Eisai Co Ltd has 291,649,140 shares outstanding.
What happened to Eisai Co Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eisai Co Ltd?
Currently, no hedge funds are holding shares in DE:EII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eisai Co Ltd
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
EII Company Deck
EII Earnings Call
Q4 2026
0:00 / 0:00
EII Stock 12 Month Forecast
Average Price Target
€29.64
▲(11.31% Upside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Kaken Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---